$27.23
Today
as of Jul 22, 16:45 ET
Last 30 days
Recent Press Releases & News
Alto Neuroscience Prices $100 Million Stock Offering
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
Overview
52-week range
$2.15
$28
95% of range
Avg surprise (last 3)
-15.6%
Avg reaction (last 2)
-7.2%
0% positive
Latest IV / EM
71%
EM ±16.2% · $25 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.80 | $-0.56 | -42.9% | -50.9% | -7.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.52 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.65 | $-0.57 | -14.0% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.53 | $-0.59 | +10.2% | — | -7.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.62 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.60 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.76 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-2.44 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.33 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.71 | -$0.65 | -9.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-27M | — | $-15M | $-19M | $-16M | — | $-19M | $-18M |
| Net income | $-26M | — | $-14M | $-18M | $-15M | — | $-17M | $-16M |
| EPS (diluted) | $-0.80 | — | $-0.52 | $-0.65 | $-0.56 | — | $-0.62 | $-0.60 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $264M | $176M | $138M | $148M | $161M | $168M | $182M | $193M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $269M | $178M | $139M | $150M | $164M | $169M | $184M | $195M |
| Total assets | $276M | $185M | $147M | $158M | $172M | $178M | $192M | $197M |
| Long-term debt | $14M | $16M | $20M | $20M | $20M | $10M | $7M | $8M |
| Total liabilities | $33M | $34M | $35M | $34M | $33M | $26M | $27M | $18M |
| Total equity | $243M | $151M | $112M | $123M | $139M | $151M | $165M | $180M |